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Background
Atazanavir (ATV) is administered at a dose of 300 mg
boosted with 100 mg of ritonavir once daily (boosted).
However, in the clinical setting use of unboosted ATV
can be warranted. Although plasma concentrations are
used clinically as a marker of drug exposure, ATV predo-
minantly acts within HIV infected cells and therefore
intracellular concentrations may better correlate with
therapeutic efficacy. To date, the factors that define ATV
flux into peripheral blood mononuclear cells (PBMC) are
not fully characterized and several efflux and influx trans-
porters may influence intracellular pharmacokinetics.
Purpose of the study
To evaluate gene expression of efflux (ABCB1, ABCC1,
ABCC2) and influx (SLCO3A1) transporters and relate
to the cellular accumulation of unboosted ATV.
Methods
Patients administered with unboosted ATV were
recruited in Torino. Written informed consent was
obtained. Main inclusion criteria were: no concomitant
interacting drugs (except for TDF), no hepatic or renal
impairment and self-reported adherence > 95%. Blood
samples were collected 22-26 h after dosing and PBMC
and plasma separated. Plasma samples were analysed by
a validated HPLC-PDA method and PBMC extracts
(intracellular) analysed using a validated LC-MS method.
The cell count and mean cellular volume (MCV) was
used for determining intracellular concentrations. Gene
expression was evaluated by relative quantification using
real time PCR.
Results
13 Caucasian patients met the inclusion criteria and were
included in the study. Median plasma ATV Ctrough was
134 ng/ml (IQR, 113-153), intracellular concentrations
were 322 ng/ml (IQR, 210-448), and the median accumu-
lation ratio (intracellular/plasma concentration) was 1.84
(IQR, 1.21–3.58). Intracellular concentrations were not
correlated with plasma concentrations (rho= -0.22
p=0.41). SLCO3A1 expression was significantly corre-
lated with cellular accumulation ratio. (rho=0.626,
p=0.022). In multivariate linear regression analyses,
SLCO3A1 expression was the only independent predictor
of ATV cellular accumulation (â=0.726, p=0.007).
Conclusions
Intracellular ATV concentrations were higher than
plasma concentrations, indicating an accumulation of
ATV in PBMC and potentially a role for influx trans-
porters. The correlation between SLCO3A1 expression
and ATV accumulation supports this hypothesis and
suggests that the SLCO3A1 uptake transporter may be a
determinant of intracellular ATV concentrations.
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